{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T05:45:23Z","timestamp":1777873523161,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:00:00Z","timestamp":1611187200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:00:00Z","timestamp":1611187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Skeletal dysplasia are genetic disorders of cartilage and bone, characterized by impairments commonly resulting in short stature, altered movement biomechanics, pain, fatigue and reduced functional performance. While current tools quantify functional mobility performance, they have not been standardly used in this population group and do not capture patient-reported symptoms such as pain or fatigue. This study evaluated a new tool, the Screening Tool for Everyday Mobility and Symptoms (STEMS), designed to accurately and objectively assess functional mobility and associated symptomology for individuals with skeletal dysplasia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Individuals aged 5\u201375\u00a0years with a skeletal dysplasia completed the STEMS, the Functional Mobility Scale (FMS) and Six Minute Walk Test (6MWT). The correlation among the STEMS, use of mobility aides, FMS and 6MWT normalised for leg length was calculated. One-way analysis of variance compared the STEMS symptomatology to normalised 6MWT distance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One hundred and fifty individuals with skeletal dysplasia (76 achondroplasia, 42 osteogenesis imperfecta, 32 other; 74\u2009&lt;\u200918\u00a0years, 76\u2009\u2265\u200918\u00a0years) participated. Almost two thirds of the group reported pain and\/or fatigue when mobilising at home, at work or school and within the community, but only twenty percent recorded use of a mobility device. The STEMS setting category demonstrated highly significant correlations with the corresponding FMS category (r\u2009=\u2009\u2212\u20090.983 to \u2212\u20090.0994, all p\u2009&lt;\u20090.001), and a low significant correlation with the normalised 6MWT distance (r\u2009=\u2009\u2212\u20090.323 to \u2212\u20090.394, all p\u2009&lt;\u20090.001). A decreased normalised 6MWT distance was recorded for individuals who reported symptoms of pain and\/or fatigue when mobilising at home or at work\/school (all p\u2009\u2264\u20090.004). Those who reported pain only when mobilising in the community had a normal 6MWT distance (p\u2009=\u20090.43\u20130.46).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The Screening Tool for Everyday Mobility and Symptoms (STEMS) is a useful new tool to identify and record mobility aide use and associated self-reported symptoms across three environmental settings for adults and children with skeletal dysplasia. The STEMS may assist clinicians to monitor individuals for changes in functional mobility and symptoms over time, identify individuals who are functioning poorly compared to peers and need further assessment, and to measure effectiveness of treatment interventions in both clinical and research settings.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13023-021-01681-z","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T07:02:57Z","timestamp":1611212577000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Development of the Screening Tool for Everyday Mobility and Symptoms (STEMS) for skeletal dysplasia"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9619-9071","authenticated-orcid":false,"given":"Penelope J.","family":"Ireland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Savarirayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tash","family":"Pocovi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracy","family":"Tate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Coussens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Tofts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Munns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verity","family":"Pacey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,21]]},"reference":[{"issue":"12","key":"1681_CR1","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1002\/ajmg.a.61366","volume":"179","author":"GR Mortier","year":"2019","unstructured":"Mortier GR, Cohn DH, Cormier-Daire V, et al. Nosology and classification of genetic skeletal disorders. Am J Med Genet A. 2019;179(12):2393\u2013419.","journal-title":"Am J Med Genet A"},{"issue":"9582","key":"1681_CR2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S0140-6736(07)61090-3","volume":"370","author":"WA Horton","year":"2007","unstructured":"Horton WA, Hall JG, Hecht JT. Achondroplasia Lancet. 2007;370(9582):162\u201372.","journal-title":"Achondroplasia Lancet"},{"issue":"3","key":"1681_CR3","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1542\/peds.2005-1440","volume":"116","author":"TL Trotter","year":"2005","unstructured":"Trotter TL, Hall JG. American Academy of Pediatrics Committee on Genetics. Health supervision for children with achondroplasia. Pediatrics. 2005;116(3):771\u201383.","journal-title":"Pediatrics"},{"issue":"3","key":"1681_CR4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/(SICI)1096-8628(19960329)62:3<255::AID-AJMG10>3.0.CO;2-J","volume":"62","author":"AG Hunter","year":"1996","unstructured":"Hunter AG, Hecht JT, Scott CI Jr. Standard weight for height curves in achondroplasia. Am J Med Genet. 1996;62(3):255\u201361.","journal-title":"Am J Med Genet"},{"key":"1681_CR5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2147\/TACG.S51485","volume":"7","author":"PJ Ireland","year":"2014","unstructured":"Ireland PJ, Pacey V, Zankl A, Edwards P, Johnston LM, Savarirayan R. Optimal management of complications associated with achondroplasia. Appl Clin Genet. 2014;7:117\u201325.","journal-title":"Appl Clin Genet"},{"issue":"3","key":"1681_CR6","first-page":"197","volume":"46","author":"B Tuysuz","year":"2004","unstructured":"Tuysuz B. A new concept of skeletal dysplasias. Turk J Pediatr. 2004;46(3):197\u2013203.","journal-title":"Turk J Pediatr"},{"issue":"1","key":"1681_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/DBP.0b013e3181c72052","volume":"31","author":"PJ Ireland","year":"2010","unstructured":"Ireland PJ, Johnson S, Donaghey S, et al. Developmental milestones in infants and young Australasian children with achondroplasia. J Dev Behav Pediatr. 2010;31(1):41\u20137.","journal-title":"J Dev Behav Pediatr"},{"issue":"6","key":"1681_CR8","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/j.1469-8749.2012.04234.x","volume":"54","author":"PJ Ireland","year":"2012","unstructured":"Ireland PJ, Donaghey S, McGill J, et al. Development in children with achondroplasia: a prospective clinical cohort study. Dev Med Child Neurol. 2012;54(6):523\u201337.","journal-title":"Dev Med Child Neurol"},{"issue":"3","key":"1681_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/00004703-199706000-00001","volume":"18","author":"ES Fowler","year":"1997","unstructured":"Fowler ES, Glinski LP, Reiser CA, Horton VK, Pauli RM. Biophysical bases for delayed and aberrant motor development in young children with achondroplasia. J Dev Behav Pediatr. 1997;18(3):143\u201350.","journal-title":"J Dev Behav Pediatr"},{"issue":"10","key":"1681_CR10","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/j.1469-8749.2011.04050.x","volume":"52","author":"PJ Ireland","year":"2011","unstructured":"Ireland PJ, McGill J, Zankl A, et al. Functional performance in young Australian children with achondroplasia. Dev Med Child Neurol. 2011;52(10):944\u201350.","journal-title":"Dev Med Child Neurol"},{"issue":"6","key":"1681_CR11","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000351374","volume":"79","author":"MB Alcausin","year":"2013","unstructured":"Alcausin MB, Briody J, Pacey V, Ault J, McQuade M, Bridge C, et al. Intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta started under three years of age. Horm Res Paediatr. 2013;79(6):333\u201340.","journal-title":"Horm Res Paediatr"},{"issue":"8","key":"1681_CR12","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s004310000505","volume":"159","author":"RH Engelbert","year":"2000","unstructured":"Engelbert RH, Uiterwaal CS, Gulmans VA, Pruijs HE, Helders PJ. Osteogenesis imperfecta: profiles of motor development as assessed by a postal questionnaire. Eur J Pediatr. 2000;159(8):615\u201320.","journal-title":"Eur J Pediatr"},{"issue":"1","key":"1681_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09638280701192857","volume":"30","author":"S Thompson","year":"2008","unstructured":"Thompson S, Shakespeare T, Wright MJ. Medical and social aspects of the life course for adults with a skeletal dysplasia: a review of current knowledge. Disabil Rehabil. 2008;30(1):1\u201312.","journal-title":"Disabil Rehabil"},{"key":"1681_CR14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/cge.13542","volume":"97","author":"SO Fredwall","year":"2019","unstructured":"Fredwall SO, Maanum G, Johansen H, Snekkevik H, Savarirayan R, Lidal IB. Current knowledge of medical complications in adults with achondroplasia: a scoping review. Clin Genet. 2019;97:179\u201397.","journal-title":"Clin Genet"},{"issue":"9","key":"1681_CR15","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1136\/jmg.35.9.705","volume":"35","author":"AG Hunter","year":"1998","unstructured":"Hunter AG, Bankier A, Rogers JG, Sillence D, Scott CI Jr. Medical complications of achondroplasia: a multicentre patient review. J Med Genet. 1998;35(9):705\u201312.","journal-title":"J Med Genet"},{"issue":"1","key":"1681_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/(SICI)1096-8628(19980616)78:1<30::AID-AJMG7>3.0.CO;2-P","volume":"78","author":"NN Mahomed","year":"1998","unstructured":"Mahomed NN, Spellmann M, Goldberg MJ. Functional health status of adults with achondroplasia. Am J Med Genet. 1998;78(1):30\u20135.","journal-title":"Am J Med Genet"},{"issue":"1","key":"1681_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12891-019-3000-7","volume":"21","author":"AG Harsevoort","year":"2020","unstructured":"Harsevoort AG, Gooijer K, van Dijk FS, van der Grijn DA, Franken AA, Dommisse AM, Janus GJ. Fatigue in adults with osteogenesis imperfecta. BMC Musculoskelet Disord. 2020;21(1):6.","journal-title":"BMC Musculoskelet Disord"},{"key":"1681_CR18","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/cge.12045","volume":"84","author":"J Hoover-Fong","year":"2013","unstructured":"Hoover-Fong J, Alade Y, Tunkel D, Schulze K, McGready J, Jallo G, Ain M, Yost T. Cross-sectional assessment of pain and physical function in skeletal dysplasia patients. Clin Genet. 2013;84:237\u201343.","journal-title":"Clin Genet"},{"issue":"5","key":"1681_CR19","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s11136-016-1455-7","volume":"26","author":"N Dhimain","year":"2018","unstructured":"Dhimain N, Albaghdadi A, Zogg CK, et al. Factors associated with health-related quality of life (HRQOL) in adults with short stature skeletal dysplasias. Qual Life Res. 2018;26(5):1337\u201348.","journal-title":"Qual Life Res"},{"issue":"5","key":"1681_CR20","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1097\/01241398-200409000-00011","volume":"24","author":"H Kerr Graham","year":"2004","unstructured":"Kerr Graham H, Harvey A, Rodda J, Nattrass GR, Pirpiris M. The Functional Mobility Scale. J Pediatr Orthop. 2004;24(5):514\u201320.","journal-title":"J Pediatr Orthop"},{"key":"1681_CR21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00003086-198109000-00015","volume":"159","author":"EE Bleck","year":"1981","unstructured":"Bleck EE. Nonoperative treatment of osteogenesis imperfecta: orthotic and mobility management. Clin Orthop Relat Res. 1981;159:111\u201322.","journal-title":"Clin Orthop Relat Res"},{"issue":"9","key":"1681_CR22","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s11136-008-9396-4","volume":"17","author":"JM Valderas","year":"2008","unstructured":"Valderas JM, Alonso J. Patient reported outcome measures: a model-based classification system for research and clinical practice. Qual Life Res. 2008;17(9):1125\u201335.","journal-title":"Qual Life Res"},{"key":"1681_CR23","unstructured":"PROMIS from the HealthMeasures Database. https:\/\/www.healthmeasures.net\/. Accessed 25 May 2020."},{"key":"1681_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1056\/NEJMoa1813446","volume":"381","author":"R Savarirayan","year":"2019","unstructured":"Savarirayan R, Irving M, Bacino CA, et al. C-type natriuretic peptide analogue therapy in children with achondroplasia. N Engl J Med. 2019;381:25\u201335.","journal-title":"N Engl J Med"},{"issue":"1","key":"1681_CR25","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s13023-018-0905-4","volume":"13","author":"B Mueller","year":"2018","unstructured":"Mueller B, Engelbert R, Baratta-Ziska F, et al. Consensus statement on physical rehabilitation in children and adolescents with osteogenesis imperfecta. Orphanet J rare Dis. 2018;13(1):158.","journal-title":"Orphanet J rare Dis"},{"issue":"10","key":"1681_CR26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2147\/JMDH.S113483","volume":"4","author":"C Marr","year":"2017","unstructured":"Marr C, Seasman A, Bishop N. Managing the patient with osteogenesis imperfecta: a multidisciplinary approach. J Multidiscip Healthc. 2017;4(10):145\u201355.","journal-title":"J Multidiscip Healthc"},{"issue":"2","key":"1681_CR27","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3109\/01942630903454930","volume":"30","author":"AR Harvey","year":"2010","unstructured":"Harvey AR, Morris ME, Graham HK, Wolfe R, Baker R. Reliability of the functional mobility scale for children with cerebral play. Phys Occup Ther Pediatr. 2010;30(2):139\u201349.","journal-title":"Phys Occup Ther Pediatr"},{"issue":"2","key":"1681_CR28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/j.1469-8749.2009.03354.x","volume":"52","author":"A Harvey","year":"2010","unstructured":"Harvey A, Baker R, Morris ME, Hough J, Hughes M, Graham HK. Does parent report measure performance? A study of the construct validity of the Functional Mobility Scale. Dev Med Child Neurol. 2010;52(2):181\u20135.","journal-title":"Dev Med Child Neurol"},{"key":"1681_CR29","first-page":"783","volume":"48","author":"PL Enright","year":"2003","unstructured":"Enright PL. The Six-Minute Walk Test. Respir Care. 2003;48:783\u20135.","journal-title":"Respir Care"},{"key":"1681_CR30","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.rmed.2005.08.003","volume":"100","author":"B Camarri","year":"2006","unstructured":"Camarri B, Eastwood PR, Cecins NM, Thompson PJ, Jenkins S. Six-minute walk distance in health subjects aged 55\u201375 years. Respir Med. 2006;100:658\u201365.","journal-title":"Respir Med"},{"key":"1681_CR31","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S1836-9553(11)70026-1","volume":"57","author":"JF De Groot","year":"2011","unstructured":"De Groot JF, Takken T. The six-minute walk test in paediatric populations. J Physiother. 2011;57:128.","journal-title":"J Physiother"},{"key":"1681_CR32","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","volume":"166","author":"American Thoracic Society","year":"2002","unstructured":"American Thoracic Society. ATS Statement: Guidelines for the Six-Minute Walk Test. Am J Respir Crit Care Med. 2002;166:111\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"1681_CR33","first-page":"79","volume-title":"Statistical power analysis for the behavioural sciences","author":"JW Cohen","year":"1988","unstructured":"Cohen JW. Statistical power analysis for the behavioural sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988. p. 79\u201381.","edition":"2"},{"key":"1681_CR34","first-page":"284","volume-title":"Statistical power analysis for the behavioural sciences","author":"JW Cohen","year":"1988","unstructured":"Cohen JW. Statistical power analysis for the behavioural sciences . 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988. p. 284\u20137.","edition":"2"},{"key":"1681_CR35","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1002\/ajmg.a.37734","volume":"170","author":"P Yap","year":"2016","unstructured":"Yap P, Savarirayan R. Emerging targeted drug therapies in skeletal dysplasia. Am J Med Genet. 2016;170:2596\u2013614.","journal-title":"Am J Med Genet"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01681-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-021-01681-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01681-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T13:33:51Z","timestamp":1670852031000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-01681-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,21]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1681"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-01681-z","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,21]]},"assertion":[{"value":"30 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was obtained through the Executive Committee of the Sydney Children\u2019s Hospitals Network Human Research Ethics Committee (HREC\/16\/SCHN\/221).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr Penny Ireland, Dr Louise Tofts and Professor Ravi Savarirayan have received fees from Biomarin Pharmaceutical for participating in advisory boards. Dr Louise Tofts is a principal investigator for the Biomarin sponsored clinical trials of Vosoritide in Achondroplasia, she does not receive any financial reimbursment for these activities.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}